Case serie...

Case series describe reports of Guillain-Barré syndrome following receipt of ChAdOx1-S/nCoV-19 vaccine

In 2 case series published in the Annals of Neurology, researchers in India and the UK reported cases of Guillain-Barré syndrome (GBS) after individuals were vaccinated against coronavirus disease 2019 (COVID-19) with the ChAdOx1-S/nCoV-19 (AstraZeneca) vaccine. In the first case series, researchers led by Boby Varkey Maramattom, MD, Aster Medcity, Kerala, India, observed 7 cases of GBS that occurred within two weeks of the first dose of vaccination. All patients progressed to areflexic quadriplegia and 6 of the 7 patients required mechanical ventilation for respiratory failure.  Further...

Study suggests convalescent plasma therapy associated with survival benefit in patients with he...

Findings from a study published in JAMA Oncology suggest a potential survival benefit in the adminis...

Risk of clinically relevant hyperglycemia with metoprolol compared to carvedilol in older adult...

BACKGROUND Although prior literature suggests that metoprolol may worsen glucose control compared to...


Suggested videos

Search:
Date
Filters:
Treatment
9:31

Treatment of hematological malignancies in 2021

Presenter: Paolo Corradini
Hematology
EHA 2021
State of t
17:17

State of the art treatment of breast cancer

Presenter: Jane Lowe Meisel
Oncology
ASCO 2021
Novelties
10:59

Novelties in the treatment of chronic myeloid leukemia

Presenter: Giuseppe Saglio
Hematology
EHA 2021
Novelties
13:14

Novelties in the treatment of follicular lymphoma

Presenter: Kai Hübel
Hematology
EHA 2021
Harnessing
10:06

Harnessing the immune system in multiple myeloma: CAR T-cell therapy and bispecific antibodies

Presenter: Xavier Leleu
Hematology
EHA 2021
Results fr
5:00

Results from the JAKARTA and JAKARTA2 trials

Presenter: Claire Harrison
Hematology
EHA 2021
Novelties
8:56

Novelties on the treatment of Multiple Myeloma

Presenter: Mohamad Mohty
Hematology
EHA 2021
Response a
6:58

Response and survival results up to five years from the KEYNOTE-052 phase 2 study

Presenter: Arjun Vasant Balar
Oncology
ASCO 2021
Expanded e
6:07

Expanded efficacy and safety analyses from CheckMate 577

Presenter: Ronan Joseph Kelly
Oncology
ASCO 2021
IMpower010
5:36

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer

Presenter: Heather A. Wakelee
Oncology
ASCO 2021
Relatlimab
6:55

Relatlimab plus nivolumab versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047

Presenter: Evan J. Lipson
Oncology
ASCO 2021
ODENZA: A
4:28

ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).

Presenter: Emeline Colomba
Oncology
ASCO 2021
Effectiven
4:27

Effectiveness and safety of apixaban versus warfarin in obese patients with nonvalvular atrial fibrillation enrolled in medicare and veteran affairs

Presenter: Steven B. Deitelzweig
Cardiology
ACC 2021
PRADA Tria
4:48

PRADA Trial: Prevention Of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: Long-term Follow-up Of A 2 X 2 Factorial, Randomized, Placebo-controlled, Double-blind Clinical Trial Of Candesartan And Metoprolol

Presenter: Siri Lagethon Heck
Cardiology
ACC 2021
ADAPTABLE
5:09

ADAPTABLE Study: Aspirin Dosing: A Patient-centric Trial Assessing Benefits And Long-term Effectiveness Trial

Presenter: William Schuyler Jones
Cardiology
ACC 2021
PARADISE-M
6:09

PARADISE-MI: Prospective Arni Versus Ace Inhibitor Trial To Determine Superiority In Reducing Heart Failure Events After Myocardial Infarction

Presenter: Marc A. Pfeffer
Cardiology
ACC 2021
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients.

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology